One Case of Liver Injury Induced by Bosentan Tablets

doi:10.19803/j.1672-8629.2019.12.10

Abstract

CLC Number:

R994.11

PAN Manmang, LIU Xiaoyan, ZUO Xiaocong, ZHOU Lingyun, GU Zhi chun. One Case of Liver Injury Induced by Bosentan Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(12): 757-758.

[1] 2015 ESC/ERS Guidelines for the diagnosis and treat ment of pulmonary hypertension[M]. European Heart Journal Advance Access published August 29, 2015.
[2] 中华医学会心血管病学分会.中国肺高血压诊断和治疗指南2018[J].中华心血管病杂志. 2018, 46(12):933-964.
[3] Barst RJ.A review of pulmonary arterial hypertension:role of ambrisentan[J]. Vasc Health Risk Manag, 2007, 3(1):11-22.
[4] 顾智淳,刘晓琰,倪晓珺,等.波生坦与华法林致INR降低1例[J].中国药物警戒, 2014, 11(6):379-380.
[5] Rubin L J, Badesch D B, Barst R J, et al.Bosentan therapy for pulmonary arterial hypertension[J].N Engl J Med,2002, 346(12):896-903.
[6] McLaughlin V V, Sitbon O, Badesch D B, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension[J]. Eur Respir J, 2005, 25(2):244-249.
[7] Sitbon O, Badesch D B, Channick R N, et al.Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension:a 1-year follow-up study[J].Chest, 2003, 124(1):247-254.
[8] Nagai Y, Okada E, Mihara S, et al.Severe Liver dysfunction due to bosentan in patient with mixed connective tissue disease[J].Eur J Dermatol, 2008, 18(2):190-191.
[9] Eriksson C,Gustavsson A,Kronvall T,et al.Hepatotoxicity by bosentan in a patient with portopulmonary hypertension:a case report and review of the literature[J]. J Gastrointesin Liver Dis, 2011, 20(1):77-80.
[10] Humbert M,Segal E S,Kiely D G,et al.Results of European postmarketing surveillance of bosentan in pulmonary hyper-tension[J].Eur Respir, 2007, 30(2):338-344.
[11] Girgis R E, Mathai S C, Krishnan J A, et al.Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases[J].J Heart Lung Transplant, 2005, 24(10):1626-1631.
[12] 葛俊波,徐永健.《内科学》[M]. 8版.人民卫生出版社,2014.
[13] Galiè N, Olschewski H, Oudiz R J, et al.Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension,Randomized, Double-Blind, Placebo-Controlled, Multicenter,Efficacy (ARIES) Study 1 and 2[J]. Circulation, 2008, 117(23):3010-3019.

[1]	SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131.
[2]	ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136.
[3]	BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140.
[4]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[5]	LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180.
[6]	FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
[7]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[8]	WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194.
[9]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[10]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[11]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[12]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[13]	LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
[14]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[15]	ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.

One Case of Liver Injury Induced by Bosentan Tablets

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics